1. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001
2. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC);Vansteenkiste;J Clin Oncol,2007
3. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Statistical principles for clinical trials;Stat Med,1999
4. Trials within trials: confirmatory subgroup analyses in controlled clinical experiments;Moyé;Control Clin Trials,2001
5. SATURN: a double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC;Cappuzzo;J Clin Oncol,2009